ArticleTherapeutics and clinical risk management2009
Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety.
Article in Therapeutics and clinical risk management, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Pharmacological Probes to Validate Biomarkers for Analgesic Drug Development.International journal of molecular sciences · 2022Pooled it
- Lacosamide add-on therapy for focal epilepsy.The Cochrane database of systematic reviews · 2021Pooled it
- Advances in Sodium Channel Modulation in Epilepsy Therapy: Focus on Eslicarbazepine, Lacosamide and Cenobamate.Biomedicines · 2026Review
- Focused ultrasound combined with drug-loaded microbubbles suppresses ictal spikes in kainic acid-induced epileptic animals.Ultrasonics sonochemistry · 2025Article
- Mutant zebrafish lacking slc25a22a show spontaneous seizures and respond to the anti-seizure medication valproic acid.Disease models & mechanisms · 2025Article
- Intravenous lacosamide for acute repetitive seizures and convulsive status epilepticus in critically ill children.Epilepsia open · 2024Article
- Use of Sodium Channel Blockers in the Thr226Met Pathologic Variant of SCN1A: A Case Report.Neuropediatrics · 2023Article
- Lacosamide dosing in patients receiving continuous renal replacement therapy.Journal of intensive care · 2023Article
- Lacosamide in monotherapy in BTRE (brain tumor-related epilepsy): results from an Italian multicenter retrospective study.Journal of neuro-oncology · 2022Article
- Epilepsy treatment in neuro-oncology: A rationale for drug choice in common clinical scenarios.Frontiers in pharmacology · 2022Review
- Review
- Effect of Lacosamide and Ethosuximide Chronic Treatment on Neural Precursor Cells and Cognitive Functions after Pilocarpine Induced Status Epilepticus in Mice.Brain sciences · 2021Article
- Effects of levetiracetam and lacosamide on therapeutic efficacy and neural function in patients with epilepsy.Experimental and therapeutic medicine · 2020Article
- Preparation, Characterization, and Stability Evaluation of Taste-Masking Lacosamide Microparticles.Materials (Basel, Switzerland) · 2019Article
- Lacosamide on background eeg activity in brain tumor-related epilepsy patients: A case series study.Brain and behavior · 2018Article
- Treatment of Refractory and Super-refractory Status Epilepticus.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2018Review
- Review
- Adjunctive lacosamide treatment for adult focal-onset epilepsy: focus on comorbid intellectual/developmental disorders and differing responses.Therapeutics and clinical risk management · 2018Article
- Antiepileptic Drug Removal by Continuous Renal Replacement Therapy: A Review of the Literature.Clinical drug investigation · 2017Review
- Pharmacotherapy for Status Epilepticus.Drugs · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lacosamide (LCM) is a novel agent that has been developed as an antiepileptic drug. In vitro studies suggest that LCM modulates voltage-gated sodium channels by enhancing their slow inactivation. In addition, LCM seems to interact with collapsin-response mediator protein 2 and thus may mediate neuronal plasticity. LCM has an elimination half-life of 13 hours, no relevant protein binding, and does not induce or inhibit enzymes of the cytochrome P450 system. No clinically significant drug-drug interactions have been discovered as yet. Experimental data suggest anticonvulsant as well as analgesic effects. Large clinical studies have demonstrated its efficacy for treatment of patients with partial seizures. LCM is well tolerated, and the most common adverse events are unspecific central nervous system and gastrointestinal effects such as dizziness, vertigo, nausea, and headache. LCM is approved for treatment of partial seizures with or without secondary generalization in the United States and the European Union within a dose range of 200 to 400 mg per day, administered twice daily. In addition to the oral formulations, an intravenous infusion solution is available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.